Why the study?
Does recombinant Angiopoietin-2 impair collateral artery growth and blood flow recovery in a mouse model of hindlimb ischaemia?
Population
Male C57BL/6 mice subjected to unilateral hindlimb ischaemia by femoral artery ligation
Comparison
Recombinant human Ang-2 injected… vs Vehicle injected intraperitoneally every other day
Design
Preclinical
Follow-up
7 days
Key result
Recombinant Ang-2 treatment significantly impaired blood flow recovery and reduced collateral arteriole diameter in a mouse model of hindlimb ischaemia.
Authors
Loading...
Should not change clinical practice; hypothesis-generating for Ang-2 targeting to promote arteriogenesis in ischaemia.
Does recombinant Angiopoietin-2 impair collateral artery growth and blood flow recovery in a mouse model of hindlimb ischaemia?
p-value: p=<0.05
In a mouse model of hindlimb ischaemia, Angiopoietin-2 impairs collateral artery growth and blood flow recovery by suppressing macrophage infiltration and downregulating angiogenic factors.
Tan et al. (2016) studied Hindlimb ischaemia. Recombinant human Ang-2 vs. Vehicle (PBS) was evaluated on Blood flow recovery (ratio of ischaemic to non-ischaemic hindlimb blood flow) (p=<0.05). Recombinant Ang-2 treatment significantly impaired blood flow recovery and reduced collateral arteriole diameter in a mouse model of hindlimb ischaemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: